Search

Your search keyword '"Mangen, M. J.J."' showing total 12 results
Start Over Author "Mangen, M. J.J." Publication Year Range Last 50 years
12 results on '"Mangen, M. J.J."'

3. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease

Author

Severs, M., Oldenburg, B., Van Bodegraven, Ad A., Siersema, P. D., Mangen, M. J.J., and initiative of Crohn’s and Colitis

Subjects
Crohn’s disease, health care costs, Gastroenterology, Journal Article, biosimilars, anti-TNF, economics, ulcerative colitis
Abstract

Objective: Inflammatory bowel disease [IBD] entails a high economic burden to society. We aimed to estimate the current and future impact of the introduction of biosimilars for infliximab on IBD-related health care costs. Methods: We designed a stochastic economic model to simulate the introduction of biosimilars in IBD, using a 5-year time horizon, based on the Dutch situation. Prevalence data on ulcerative colitis [UC] and Crohn's disease [CD] and IBD-related health care costs data were used as input. Assumptions were made on price reductions of anti-tumour necrosis factor [TNF] therapy, increase of anti-TNF prescription rate, and development of hospitalization costs. The base case scenario included a gradual decrease in prices of biosimilars up to 60%, a gradual decrease in prices of original anti-TNF compounds up to 50%, and an annual increase of anti-TNF prescription rate of 1%, and this was compared with no introduction of biosimilars. Sensitivity analyses were performed. Results: For the base case, cost savings over the total of 5 years were on average €9,850 per CD patient and €2,250 per UC patient, yielding in €493 million total cost savings [a reduction of 28%] for The Netherlands. Results were predominantly determined by price reduction of anti-TNF therapy, threshold price reduction at which physicians switch patients towards biosimilars and the extent to which switching will take place. Conclusions: The introduction of biosimilars for infliximab can be expected to have a major impact on the cost profile of IBD. The economic impact will depend on local pricing, procurement policies and the physician's willingness to switch patients to biosimilars.

Published
2017

6. Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease

Author

Severs, M., Mangen, M. J.J., van der Valk, M. E., Fidder, H. H., Dijkstra, G., van der Have, M., Van Bodegraven, Ad A., de Jong, J., van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, C. H. M., Jansen, J. M., van de Meeberg, Paul C, Mahmmod, N., Ponsioen, Cyriel Y, Vermeijden, Jacob R., Van der Meulen-de Jong, Andrea E, Pierik, M., Siersema, P. D., Oldenburg, B., COIN study group and the Dutch Initiative on Crohn and Colitis, Severs, M., Mangen, M. J.J., van der Valk, M. E., Fidder, H. H., Dijkstra, G., van der Have, M., Van Bodegraven, Ad A., de Jong, J., van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, C. H. M., Jansen, J. M., van de Meeberg, Paul C, Mahmmod, N., Ponsioen, Cyriel Y, Vermeijden, Jacob R., Van der Meulen-de Jong, Andrea E, Pierik, M., Siersema, P. D., Oldenburg, B., and COIN study group and the Dutch Initiative on Crohn and Colitis

Published
2017

7. Targeted outreach hepatitis B vaccination program in high-risk adults : The fundamental challenge of the last mile

Author

Mangen, M. J.J., Stibbe, H, Urbanus, A., Siedenburg, E C, Waldhober, Q, de Wit, G. A., Steenbergen, Eric J, the National Working Group of hepatitis B behavioural risk-groups vaccination program, Mangen, M. J.J., Stibbe, H, Urbanus, A., Siedenburg, E C, Waldhober, Q, de Wit, G. A., Steenbergen, Eric J, and the National Working Group of hepatitis B behavioural risk-groups vaccination program

Published
2017

8. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease

Author

UMC Utrecht, Unit Opleiding Aios, Cancer, MS MDL 1, Infection & Immunity, HEE, Severs, M., Oldenburg, B., Van Bodegraven, Ad A., Siersema, P. D., Mangen, M. J.J., initiative of Crohn’s and Colitis, UMC Utrecht, Unit Opleiding Aios, Cancer, MS MDL 1, Infection & Immunity, HEE, Severs, M., Oldenburg, B., Van Bodegraven, Ad A., Siersema, P. D., Mangen, M. J.J., and initiative of Crohn’s and Colitis

Published
2017

9. Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile

Author

HEE, Circulatory Health, JC onderzoeksprogramma Methodologie, Mangen, M. J.J., Stibbe, H, Urbanus, A., Siedenburg, E C, Waldhober, Q, de Wit, G. A., Steenbergen, Eric J, the National Working Group of hepatitis B behavioural risk-groups vaccination program, HEE, Circulatory Health, JC onderzoeksprogramma Methodologie, Mangen, M. J.J., Stibbe, H, Urbanus, A., Siedenburg, E C, Waldhober, Q, de Wit, G. A., Steenbergen, Eric J, and the National Working Group of hepatitis B behavioural risk-groups vaccination program

Published
2017

10. Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease

Author

UMC Utrecht, Unit Opleiding Aios, Cancer, HEE, MS MDL 1, Infection & Immunity, Severs, M., Mangen, M. J.J., van der Valk, M. E., Fidder, H. H., Dijkstra, G., van der Have, M., Van Bodegraven, Ad A., de Jong, J., van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, C. H. M., Jansen, J. M., van de Meeberg, Paul C, Mahmmod, N., Ponsioen, Cyriel Y, Vermeijden, Jacob R., Van der Meulen-de Jong, Andrea E, Pierik, M., Siersema, P. D., Oldenburg, B., COIN study group and the Dutch Initiative on Crohn and Colitis, UMC Utrecht, Unit Opleiding Aios, Cancer, HEE, MS MDL 1, Infection & Immunity, Severs, M., Mangen, M. J.J., van der Valk, M. E., Fidder, H. H., Dijkstra, G., van der Have, M., Van Bodegraven, Ad A., de Jong, J., van der Woude, C Janneke, Romberg-Camps, Mariëlle J L, Clemens, C. H. M., Jansen, J. M., van de Meeberg, Paul C, Mahmmod, N., Ponsioen, Cyriel Y, Vermeijden, Jacob R., Van der Meulen-de Jong, Andrea E, Pierik, M., Siersema, P. D., Oldenburg, B., and COIN study group and the Dutch Initiative on Crohn and Colitis

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results